Sara de Cassia Tornier1, Fernanda Joly Macedo2, Laurindo Moacir Sassi2, Juliana Lucena Schussel3,4. 1. Postgraduate Program in Dentistry, Universidade Federal Do Paraná, Curitiba, Paraná, Brazil. 2. Department of Oral and Maxillofacial Surgery, Erasto Gaertner Cancer Center, Curitiba, Paraná, Brazil. 3. Postgraduate Program in Dentistry, Universidade Federal Do Paraná, Curitiba, Paraná, Brazil. juliana.schussel@ufpr.br. 4. Department of Oral and Maxillofacial Surgery, Erasto Gaertner Cancer Center, Curitiba, Paraná, Brazil. juliana.schussel@ufpr.br.
Abstract
PURPOSE: Cancer and its therapies can have a significant impact on general and oral health and, therefore, cause a reduction in patients' quality of life (QoL). The study aimed to evaluate the QoL of cancer patients who use antiresorptive and anti-angiogenic medications with or without the development of medication-related osteonecrosis of the jaws (MRONJ). METHODS: Sixty-two patients diagnosed with cancer under antiresorptive therapy answered three instruments from the European Organization for Cancer Research and Treatment (EORTC). The first questionnaire (QLQ-C30) aimed to measure the overall QoL, the second (QLQ-ELD14) is a complementary module for elderly patients, and the third (QLQ-OH15) aimed to assess oral health related to QoL. RESULTS: The mean age of the patients was 62.19 years, and 12.9% developed MRONJ. There was no significant difference between sex and MRONJ. Among the QLQ-C30 scales, the item "role functioning (RF2)" presented a significant result (p = 0.019). Those patients without MRONJ had a better function performance both in their daily chores and in their free time. Age was not associated to MRONJ, although some concerns are common to the elderly and cancer patients. QoL related to oral health presented a significant result (p = 0.048) showing that MRONJ has a negative impact on patients' QoL. CONCLUSION: Our results showed that MRONJ has a significant impact on the general and oral QoL of cancer patients, and therefore prevention and awareness must be a priority.
PURPOSE:Cancer and its therapies can have a significant impact on general and oral health and, therefore, cause a reduction in patients' quality of life (QoL). The study aimed to evaluate the QoL of cancerpatients who use antiresorptive and anti-angiogenic medications with or without the development of medication-related osteonecrosis of the jaws (MRONJ). METHODS: Sixty-two patients diagnosed with cancer under antiresorptive therapy answered three instruments from the European Organization for Cancer Research and Treatment (EORTC). The first questionnaire (QLQ-C30) aimed to measure the overall QoL, the second (QLQ-ELD14) is a complementary module for elderly patients, and the third (QLQ-OH15) aimed to assess oral health related to QoL. RESULTS: The mean age of the patients was 62.19 years, and 12.9% developed MRONJ. There was no significant difference between sex and MRONJ. Among the QLQ-C30 scales, the item "role functioning (RF2)" presented a significant result (p = 0.019). Those patients without MRONJ had a better function performance both in their daily chores and in their free time. Age was not associated to MRONJ, although some concerns are common to the elderly and cancerpatients. QoL related to oral health presented a significant result (p = 0.048) showing that MRONJ has a negative impact on patients' QoL. CONCLUSION: Our results showed that MRONJ has a significant impact on the general and oral QoL of cancerpatients, and therefore prevention and awareness must be a priority.
Entities:
Keywords:
Medication-related osteonecrosis of the jaws; Oral health; Quality of life
Authors: Rebecca Anne Miksad; Kuan-Chi Lai; Thomas Benton Dodson; Sook-Bin Woo; Nathaniel Simon Treister; Omosalewa Akinyemi; Marian Bihrle; Guy Maytal; Meredith August; G Scott Gazelle; J Shannon Swan Journal: Oncologist Date: 2011-01-06
Authors: Olga Di Fede; Vera Panzarella; Rodolfo Mauceri; Vittorio Fusco; Alberto Bedogni; Lorenzo Lo Muzio; Giuseppina Campisi Journal: Biomed Res Int Date: 2018-09-16 Impact factor: 3.411
Authors: Sebastian Blatt; Maximilian Krüger; Peer W Kämmerer; Daniel G E Thiem; Philipp Matheis; Anne-Katrin Eisenbeiß; Jörg Wiltfang; Bilal Al-Nawas; Hendrik Naujokat Journal: J Clin Med Date: 2022-01-28 Impact factor: 4.241
Authors: Anna Winter; Stefan M Schulz; Marc Schmitter; Roman C Brands; Anton Straub; Alexander Kübler; Anna Borgmann; Stefan Hartmann Journal: Int J Environ Res Public Health Date: 2022-09-16 Impact factor: 4.614